Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a pharmaceutical company specializing in treatments for tumors and viruses, has initiated the exercise of existing warrants which is expected to ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

Michael Boyle is an experienced financial professional with more than 10 years working with financial planning, derivatives, equities, fixed income, project management, and analytics. Vikki ...

Fermenta Biotech Limited, Indias leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and ...

“If small biotech companies like ours are forced to scale back or shut down, it will not just be a loss for scientific ...

In our analysis, these 12 brokerage accounts stand out as the best choices for stock trading, due to their low fees, strong platforms and quality customer support. Many, or all, of the products ...

Donald Trump Jr. and Eric Trump are participating in Dominari Holdings' private placement and are joining its advisory board.

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma.

Maxim downgraded Moleculin Biotech (MBRX) to Hold from Buy.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...